In preclinical models, MEK inhibition was shown to delay the progression of MOC1 and MOC2 tumors in mice,17 18 and in SCC-VII HNC model,19 it was shown that treatment of tumor-bearing mice with trametinib induced CD8+ T cell infiltration into the TME and upregulated expression of programmed death-ligand 1 (PD-L1) by the tumor cells. Here, CD8A is linked to neoplasm.